The Sarcopenia Treatment Market is expected to grow at a CAGR of 5.71% during the forecast period. The market is expected to grow due to the rising of the geriatric population, as with growing age the chance of muscle weakness gets increased. The risk of disability is 1.5 to 4.6 times higher in older adults with sarcopenia than older adults without sarcopenia.
In accordance with the data from World Population Prospects: the 2019 Revision, by 2050, 1 in 6 people in the world will be over age 65 (16%), up from 1 in 11 in 2019 (9%) and by 2050, 1 in 4 persons living in Europe and Northern America could be aged 65 or over. In 2018, the persons aged 65 or above outnumbered children under five years of age globally. Therefore the number of persons aged 80 years or over is projected to triple, from 143 million in 2019 to 426 million in 2050. Hence with the growing aging population and increasing interest in preventive healthcare results in rising adoption of supplements is a major factor in boosting the demand for sarcopenia treatment.
Key Market Trends
Protein Supplement is Anticipated to Show Considerable Growth During the Forecast Period
Nutrition supplementation along with exercise is an effective strategy to decrease all the macronutrients can be used for energy production in human body, but only protein serves as a structural and functional compound in all organs and cells, which is why its demand is likely to increase in future.
Proteins, especially rich in leucine, are the most effective branched-chain amino acid at stimulating muscle protein synthesis. Protein supplements help to retain the muscle mass muscle strength, and endurance. Recent evidence by Anne-Julie Tessier et al., supports a higher protein intake recommendation of 1.0–1.2 g/kg/day in healthy older adults; an evenly distributed mealtime protein intake or minimal protein per meal is considered to be beneficial. Hence all these factors are expected to drive the overall market growth.
North America is Expected to Dominate the Sarcopenia Treatment Market
North America is expected to hold a dominant position in the sarcopenia treatment market, owing to presence of developed healthcare facilities and technological advancements that are likely to fuel growth of the sarcopenia treatment market during the forecast period.
As per the Population Reference Bureau, the number of Americans ages 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16% to 23%. About 45% of older adults in the United States are affected by sarcopenia, which is expected to increase as the population ages. In addition, there is a considerable economic burden of related healthcare expenditures for sarcopenia in the United States which is estimated to be USD 18.5 billion annually. Furthermore, the health awareness and active presence of major players are likely to drive the studied market growth in this region.
In addition, the rising population, increased research activities, and awareness in developing countries are the factors contributing to the growth of the sarcopenia treatment market in Asia region.
The key manufacturers in the sarcopenia treatment market have been focusing on novel marketing and sales strategies to increase their product penetration. Along with that, rising inclination towards online distribution channel have been playing a vital role. Few of the key market players in the studied market are GlaxoSmithKline plc, Eli Lilly and Company, Nestlé S.A., Sanofi S.A., Bayer AG among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support